If you have been reading the MSB threads there has been an argument for about 5 years where one group say the business model is unproven and so they won't invest just yet.
Those in favour of stem cells say it is a new and disruptive technology, so what it boils down to in my mind, is that some accept higher risk reward while others say they will buy in once income is forthcoming.
What it means for RGS, IMO is that MSB will lead the way and if it surges so will the smaller stem cell companies.
The Cures act in the States has however lowered the bar for MSB and I am now confident there will be sales by the end of this year.
I have also invested in the companies above as I believe the stem cell sector will surge in unison.
We should have a pretty good idea of the future prospects of all stem cell companies by Dec 2017
Ann: Q4 2016 Update, page-9
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
